Education Material

Interacting with the FDA (How to avoid a clinical hold)

This lecture explains when you need an IND and what it should and should not contain to avoid clinical hold ups with the FDA. Reasons for Phase I, 2 and 3 clinical holds are discussed along with clinical reporting requirements.

Introduction to Drug Discovery Research

A lecture discussing the current status, historical perspective and the future challenges of Drug Discovery and Development. 

This is the first lecture in a 15-week course, Introduction to Drug Discovery Research, given at Johns Hopkins...

It’s all about dose…. Toxicology in Drug Discovery and Development

Nonclinical toxicology studies are critical during drug development due to the scientific need and regulatory requirement to collect information to define the toxicity profile and provide an evaluation of the relationship of dose and exposure to...

Laboratory for Drug Discovery in Neurodegeneration (LDDN)

Learn more about the Laboratory for Drug Discovery in Neurodegeneration (LDDN) at the Harvard NeuroDiscovery Center. This presentation discusses the Center's mission, staff, program areas, projects and more.'

Lead Optimization

A lecture on hit to lead and lead optimization.

This is the tenth lecture in a 15-week course, Introduction to Drug Discovery Research, given at Johns Hopkins University School of Medicine, discussing the various aspects of the drug discovery...

Molecular Subtypes in Glioblastoma Multiforme: Integrated Analysis Using Agilent GeneSpring and Mass Profi ler Professional Multi-Omics Software

Agilent GeneSpring and Mass Profi ler Professional (MPP) software was used to perform integrated multi-omics analysis of mRNA expression, miRNA expression, protein expression, and copy number aberration (CNA) associated with glioblastoma multiforme...

NeuroTranslational Drug Discovery Program

Learn more about the Brain Science Institute NeuroTranslational Drug Discovery Program at Johns Hopkins.  This presentation explains how the program got its start, the mission, the staff, the capabilities and future plans.

Pharmaceutical Applications Compendium Purity and Impurity Analysis

Cost-effective methods for purity and impurity analysis, reducing analysis time and solvent consumption while remaining compliant with pharmacopeia guidelines.

Pharmaceutical Impurity Analysis Solutions

Primer: 1. PHARMACEUTICAL IMPURITY ANALYSIS OVERVIEW AND REGULATORY SITUATION 2. ANALYTICAL TECHNOLOGIES FOR IMPURITY PROFILING IN PHARMACEUTICAL DEVELOPMENT 3. A SELECTION OF AGILENT APPLICATION SOLUTIONS FOR THE THREE MAJOR TYPES OF IMPURITIES

Rapid and Robust Early ADME Solutions

By eliminating compounds with toxic liabilities during discovery, instead of during clinical development, more resources can be focused on compounds with a greater likelihood of success. Agilent presents rapid and robust solutions for early ADME...